香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2373） 自願公告 市場股份回購 本公告由美麗田園醫療健康產業有限公司（「本公司」，連同其附屬公司統稱「本集 團」）自願刊發。 本公司欣然公佈，本公司於2025年10月15日於市場購回50,000股本公司股份，總交 易金額約1,694,810港元，交易平均價約每股33.90港元。 本公司董事（「董事」）會（「董事會」）認為，目前的股份成交價並不反映股份的內在價 值和本公司的實際業務前景。董事會相信，股份購回體現了管理層對企業長期價值 的堅定信心，有利於提升本集團資本市場價值及股東回報能力。本次股份購回符合 本公司及其股東的整體利益。 董事會本次回購是通過於2025年6月27日舉行的本公司股東週年大會（「 ...

每经AI快讯，美丽田园医疗健康(02373.HK)早盘涨近5%，截至发稿，涨4.7%，报37.42港元，成交额 1172.89万港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - Meili Tianyuan Medical Health (02373) is set to acquire 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan (approximately 1.369 billion HKD), which is expected to enhance its market position and expand its store network significantly [1] Group 1: Acquisition Details - The acquisition of Shanghai Siyuanli Industrial will allow Meili Tianyuan to own the high-end skincare brand "Siyuanli" in China [1] - Post-acquisition, the number of stores is projected to reach 734, indicating rapid expansion [1] Group 2: Market Position and Growth Potential - Meili Tianyuan is recognized as a leading player in the domestic beauty and medical beauty service sector, with a strong brand reputation and operational capabilities [1] - The company is expected to see performance growth driven by deepening digital transformation, improved supply chain layout, and ongoing store expansion [1] Group 3: Analyst Insights - Huachuang Securities has issued a report projecting a compound annual growth rate for profits over the next three years, alongside a target price of 43.56 HKD, maintaining a "strong buy" rating [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) is set to acquire 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan (approximately 1.369 billion HKD), which is expected to significantly expand its store network and strengthen its market position in the high-end skincare sector [1]. Company Summary - Meili Tianyuan Medical Health's stock rose nearly 5% in early trading, reaching 37.42 HKD with a trading volume of 11.7289 million HKD [1]. - The acquisition of Shanghai Siyuanli, which owns the high-end skincare brand "Siyuanli," is anticipated to increase the number of stores to 734 [1]. - The company aims to leverage its "Double Beauty + Double Healthcare" business model to enhance its industry position and market share [1]. Industry Summary - Huachuang Securities has noted that Meili Tianyuan is a leading player in the domestic beauty and medical beauty service sector, with a strong brand reputation and operational capabilities [1]. - The company is expected to see growth in performance due to deepening digital transformation, improved supply chain layout, and ongoing store expansion [1]. - The target price for Meili Tianyuan is set at 43.56 HKD, maintaining a "strong buy" rating based on projected profit compound growth over the next three years and comparable company valuations [1].

Core Viewpoint - Meili Tianyuan Medical Health announced a cash acquisition of 100% equity in Shanghai Siyuanli Industrial for 1.25 billion yuan, equivalent to approximately 1.369 billion HKD, which aims to strengthen its market share in the high-end beauty sector in first-tier cities [1] Group 1: Acquisition Details - The acquisition involves a share purchase agreement between Meili Tianyuan's wholly-owned subsidiary Shanghai Meili Tianyuan Medical Health and SYL Holding, along with Shanghai Anyan [1] - Upon completion of the transaction, Shanghai Siyuanli Industrial will become a wholly-owned subsidiary of Meili Tianyuan [1] - The sellers, SYL Holding and Shanghai Anyan, have committed to completing the transaction as per the agreement, pending customary conditions [1] Group 2: Market Impact - The acquisition is expected to further consolidate Meili Tianyuan's position in the high-end beauty market within first-tier cities [1]

Core Viewpoint - The acquisition of Shanghai Siyuanli Industrial Co., Ltd. by Meili Tianyuan Medical Health is a strategic move to reshape the competitive landscape of the high-end beauty industry in China's high-tier cities, following the successful acquisition of Nairui in 2024 [1][3]. Group 1: Acquisition Details - Meili Tianyuan Medical Health and its subsidiaries have agreed to acquire 100% of the issued shares of Shanghai Siyuanli for a consideration of RMB 1.25 billion [1]. - The acquisition will involve the issuance of 15.7981 million shares to SYL Holding, representing approximately 6.70% of the total issued shares as of the announcement date [1]. Group 2: Target Company Overview - Shanghai Siyuanli, established on December 31, 2009, is a leading brand in China's high-end beauty service industry, focusing on skincare products and professional beauty experiences for women in high-tier cities [2]. - As of June 30, 2025, the target company operates 163 beauty stores and 19 medical beauty clinics across 48 cities in China, with over 90% of its revenue coming from stores in the top 20 first-tier and new first-tier cities [2]. Group 3: Strategic Implications - The acquisition is expected to significantly expand the store network to 734 locations, enhancing the customer base and market share of Meili Tianyuan [3]. - The integration will leverage five core capabilities, including chain management, customer lifecycle management, medical service upgrades, AI transformation, and supply chain integration, to maximize synergies and drive revenue and profit growth [3].

Group 1 - The company, 美丽田园医疗健康, has entered into a conditional share purchase agreement to acquire 100% of the issued shares of 上海思妍丽实业 for a consideration of RMB 1.25 billion (approximately HKD 1.369 billion) [1] - As part of the consideration, 15.7981 million shares will be issued to SYL Holding, representing about 6.70% of the total issued shares as of the announcement date, and approximately 6.28% of the total issued shares post-acquisition [1] - The target company, 思妍丽, is a leading brand in China's high-end beauty service industry, operating 163 beauty stores and 19 medical beauty clinics across 48 cities as of June 30, 2025 [2] Group 2 - The acquisition is seen as a significant milestone for the company, following the successful acquisition of 奈瑞儿 in 2024, and is expected to reshape the competitive landscape of the high-end beauty industry in China's top-tier cities [2] - Post-acquisition, the company's store network will expand to 734 locations, significantly increasing its membership base and enhancing its market position [2] - The company plans to leverage five core capabilities, including chain management and AI transformation, to maximize synergies and drive revenue and profit growth [3]

Core Viewpoint - The acquisition of 100% equity in Shanghai Siyuan Lishi by Meili Tianyuan Medical Health is a strategic move to enhance its position in the high-end beauty service industry in China, with a total consideration of RMB 1.25 billion (approximately HKD 1.369 billion) [1][2]. Group 1: Acquisition Details - The agreement involves the conditional sale of shares by SYL Holding and Shanghai Anyan, with Meili Tianyuan Medical Health and Shanghai Meili Tianyuan as the buyers [1]. - The acquisition will result in the issuance of 15.7981 million consideration shares, representing approximately 6.70% of the total issued shares as of the announcement date [1]. - The company will apply for the listing and trading of the consideration shares on the Stock Exchange [1]. Group 2: Target Company Overview - The target company, established in December 2009, is a leading brand in China's high-end beauty service sector, known for its skincare products and services [2]. - As of June 30, 2025, the target company operates 163 beauty stores and 19 medical beauty clinics across 48 cities in China, with over 90% of its revenue coming from first-tier and new first-tier cities [2]. - According to Frost & Sullivan, the target company's brand ranks as the third-largest beauty service brand in China based on 2024 revenue [2]. Group 3: Strategic Implications - This acquisition marks a significant milestone for the company, following its successful acquisition of Nairui'er in 2024, and is expected to reshape the competitive landscape of the high-end beauty industry in high-tier cities [3]. - Post-acquisition, the company's store network will expand to 734 locations, significantly increasing its membership base [3]. - The integration will leverage five core capabilities, including chain management and AI-driven transformation, to maximize synergies and enhance revenue and profit growth [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考之用，並不構成收購、購買或認購本公司任何證券之邀請或要約。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2373） 有關涉及根據特別授權發行對價股份 收購目標公司100%已發行股份之主要交易 財務顧問 收購事項 董事會欣然宣佈，於2025年10月15日（聯交所交易時段前），本公司、上海美麗田 園醫療健康、SYL Holding及上海安妍訂立股份購買協議，據此，（其中包括） SYL Holding及上海思妍（均作為賣方）有條件同意出售，而本公司及上海美麗田 園醫療健康（均作為買方）有條件同意收購上海思妍麗實業100%已發行股份，對 價為人民幣1,250.0百萬元（相當於約1,369.2百萬港元）。 – 1 – 作為對價的一部分，對價股份 ...

Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].